Head of Moderna warns effectiveness of jabs on Omicron is probably ‘not going to be good’
Head of Moderna warns ‘it will be MONTHS’ before there is a specific jab to fight Omicron after three more variant cases are confirmed in Scotland bringing UK total to 14
Stephane Bancel, head of Moderna, warned vaccines were likely to struggle against the Omicron variantExperts say jabs are likely to be less effective against infection, but still protect well against hospitalisationScotland announced one new Omicron case in Lanarkshire and two more in the Glasgow area today It comes after face masks again became mandatory on public transport and in shops across England
<!–
<!–
<!–<!–
<!–
(function (src, d, tag){
var s = d.createElement(tag), prev = d.getElementsByTagName(tag)[0];
s.src = src;
prev.parentNode.insertBefore(s, prev);
}(“https://www.dailymail.co.uk/static/gunther/1.17.0/async_bundle–.js”, document, “script”));
<!–
DM.loadCSS(“https://www.dailymail.co.uk/static/gunther/gunther-2159/video_bundle–.css”);
<!–
Covid vaccine maker Moderna warned today that it will take months to develop an Omicron-specific booster jab as Scotland detected three more cases of the mutant strain.
Stephane Bancel, chief executive at Massachusetts-based vaccine manufacturer, said he expects the highly-evolved Covid variant to cause a ‘material drop’ in the effectiveness of existing vaccines, warning that the result was ‘not going to be good’.
He warned that it will take until summer 2022 for Moderna to develop a new vaccine and scale up manufacturing to vaccinate entire populations.
Scientists say it will take two weeks to truly work out how effective jabs are against Omicron, which has twice as many mutations on its spike protein as Delta. The strain is expected to make current vaccines significantly weaker at preventing infections, but it’s less clear how it will impact hospitalisations and deaths.
Britain yesterday expanded its current booster rollout for all adults over 18. Even though the vaccines are expected to be much weaker against Omicron, it is hoped that topping up everyone’s immunity to very high levels will offer an extra line of defence against the incoming wave.
Scottish health authorities announced three more Omicron cases overnight, bringing the UK total to 14. Labs across the country are probing hundreds more probable cases and there are signs the strainis already spreading in the community.
Boris Johnson will hold a Downing Street press conference this afternoon to give an update on the Covid situation and lay out the suite of measures that kicked in this morning to tackle the variant.
From 4am, face masks were again compulsory in shops and on public transport in England. Those who are close contacts of potential Omicron cases must also self-isolate for ten days, regardless of vaccination status. Double-vaccinated people arriving in the UK are now also required to self-isolate for two days, and only leave their homes when they have received a negative PCR test.
Vaccine-makers Moderna and Pfizer are already working on Covid vaccines that could tackle the Omicron strain, if it poses a problem for the current crop of vaccines, but they won’t be ready until mid-2022
The Botswana variant has around 50 mutations and more than 30 of them are on the spike protein. The current crop of vaccines trigger the body to recognise the version of the spike protein from older versions of the virus. But the mutations may make the spike protein look so different that the body’s immune system struggles to recognise it and fight it off. And three of the spike mutations (H665Y, N679K, P681H) help it enter the body’s cells more easily. Meanwhile, it is missing a membrane protein (NSP6) which was seen in earlier iterations of the virus, which experts think could make it more infectious. And it has two mutations (R203K and G204R) that have been present in all variants of concern so far and have been linked with infectiousness
Mr Bancel told the Financial Times: ‘There is no world, I think, where [the effectiveness] is the same level… we had with Delta.
‘I think it’s going to be a material drop [in vaccine effectiveness]. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to… are like “this is not going to be good”.’
The Moderna chief executive’s comments were in stark contrast to other vaccine manufacturers who have sought to emphasise the importance of vaccines.
Scott Gottlieb, a director at Pfizer, told CNBC yesterday: ‘There’s a reasonable degree of confidence in vaccine circles that [with] at least three doses… the patient is going to have fairly good protection against this variant.’
Moderna and Pfizer’s vaccines were both used in the initial roll out, and are available as booster doses. Figures show some 2.8million Moderna and 45million Pfizer jabs have been dished out in the UK so far.
Mr Bancel told the Financial Times that his company could deliver between two to three billion doses in 2022, but added it would be dangerous to shift all production to an Omicron-specific shot while other variants of the virus remained in circulation.
A raft of new restrictions came into force in England today but it stopped short of ‘Plan B’, which would also see vaccine passports and work from home guidance return.
Dr Jenny Harries told BBC Radio 4’s Today programme that the advice from the Scientific Advisory Group for Emergencies (SAGE) ‘has shown that if we have significant surges in Covid cases, then actually working from home is one of the key ones to implement and that’s why it is in Plan B’.
‘But it’s probably worth just thinking through at the moment; although I’m sure we will have more cases announced, we do only have five confirmed cases (of the new Omicron variant in England) and 10 highly probable at the moment.
‘So it’s a very early stage for this, I think, but certainly, if we see surges, then working from home will be a good thing to do.’
Speaking earlier about vaccine effectiveness, she said it is highly likely that the UK’s vaccination programme will be beneficial in the face of the Omicron variant but experts also expect vaccine effectiveness to be reduced.
She said the current understanding is that the booster will ‘shoot up your immunity levels and so getting that high background level of immunity on a population basis may, to some extent, counter the reduced effectiveness against this particular variant’.
She added that there is a need to ‘be really careful about interpreting the data’ after suggestions from South Africa that the variant is causing mild illness, saying that the UK has an older population, with an average age of 41, compared with 27 in South Africa.
Asked about the prospect of Christmas plans being called off, Professor Paul Moss, from the Institute of Immunology and Immunotherapy at the University of Birmingham and a member of the Scientific Advisory Group for Emergencies (Sage), told Sky News: ‘I don’t think we need to worry too much about that at this stage… the measures that we got in place have a good chance of gaining some control here.
‘The two ways that we’re adopting to try and control this are: one, in behavioural change to reduce transmission: the travel restrictions; more lateral flows; masking.
‘And the second big factor is the immunity and we know that we may lose some immunity with this virus. So what is happening is we are boosting our immune levels to super-high levels with the plans that were introduced yesterday, and that should retain some protection.
‘What we’ve seen with Covid is that things change very rapidly. And I think we need at least three weeks to assess this.
‘We need excellent epidemiology and within the laboratory people are testing the resistance of the virus against vaccinated samples. So we will need that sort of time. And we will know a lot more before Christmas.’
He added: ‘You probably saw that the doctor in South Africa who initially identified it had seen relatively mild cases, which is very encouraging.
‘However, you know, that’s a much younger population.
‘It’s the elderly population, we need to worry about – in South Africa only 6% are above 65 years whereas we’ve got a much higher proportion.’
